Drug Delivery by an Enzyme‐Mediated Cyclization of a Lipid Prodrug with Unique Bilayer‐Formation Properties
- 17 February 2009
- journal article
- research article
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 48 (10) , 1823-1826
Abstract
Special delivery: Liposomal drug‐delivery systems in which prodrugs are activated specifically by disease‐associated enzymes have great potential for the treatment of severe diseases, such as cancer. A new type of phospholipid‐based prodrug has the ability to form stable small unilamellar vesicles (see picture). Activation of the prodrug vesicles by the enzyme sPLA2 initiates a cyclization reaction, which leads to the release of the drug. magnified imageKeywords
This publication has 24 references indexed in Scilit:
- Molecular Basis of Phospholipase A2 Activity toward Phospholipids with sn-1 SubstitutionsBiophysical Journal, 2008
- Nanocarriers as an emerging platform for cancer therapyNature Nanotechnology, 2007
- Biomimetic pH Sensitive Polymersomes for Efficient DNA Encapsulation and DeliveryAdvanced Materials, 2007
- Secretory Phospholipase A2Hydrolysis of Phospholipid Analogues Is Dependent on Water Accessibility to the Active SiteJournal of the American Chemical Society, 2007
- Synthesis of anti-tumour phosphatidylinositol analogues from glucose by the use of ring-closing olefin metathesisOrganic & Biomolecular Chemistry, 2004
- Designing materials for biology and medicineNature, 2004
- Drug Delivery Systems: Entering the MainstreamScience, 2004
- Enzymatic Release of Antitumor Ether Lipids by Specific Phospholipase A2Activation of Liposome-Forming ProdrugsJournal of Medicinal Chemistry, 2004
- Polymer VesiclesScience, 2002
- Liposome application: problems and prospectsCurrent Opinion in Colloid & Interface Science, 2001